Unique ID issued by UMIN | UMIN000005120 |
---|---|
Receipt number | R000006086 |
Scientific Title | Clinical trial to investigate safety and feasibility of Roux-Y with aboral pouch reconstruction after laparoscopically assisted total gastrectomy |
Date of disclosure of the study information | 2011/06/01 |
Last modified on | 2013/10/22 13:19:48 |
Clinical trial to investigate safety and feasibility of Roux-Y with aboral pouch reconstruction after laparoscopically assisted total gastrectomy
Safety and feasibility of Roux-Y with aboral pouch reconstruction after laparoscopically assisted total gastrectomy
Clinical trial to investigate safety and feasibility of Roux-Y with aboral pouch reconstruction after laparoscopically assisted total gastrectomy
Safety and feasibility of Roux-Y with aboral pouch reconstruction after laparoscopically assisted total gastrectomy
Japan |
gastric cancer
Gastrointestinal surgery |
Malignancy
NO
To investigate safety and feasibility of Roux-Y with aboral pouch reconstruction after laparoscopically assisted total gastrectomy
Safety
Confirmatory
Explanatory
Phase I
Postoperative hospital stay
Interventional
Single arm
Non-randomized
Open -no one is blinded
Historical
1
Treatment
Maneuver |
Patients participated in this study undergo laparoscopically assisted total gastrectomy with Roux-Y with aboral pouch reconstruction.
20 | years-old | <= |
85 | years-old | >= |
Male and Female
1) A gastric cancer patient diagnosed as clinical stage 1A-2B (Japanese Classification of Gastric Carcinoma The 14th Edition).
2) Planned to receive laparoscopically assisted total gastrectomy.
3) ECOG Performance Status Scale: 0-1.
4) Greater than or equal to 20 years of age and less than or equal to 85 years of age.
5) BMI (Body Mass Index): less than or equal to 25 Kg/m2
6) Meet the above-mentioned conditions and able to provide written informed consent.
1) Neo-adjuvant chemotherapy within four weeks prior to the operation.
2) Coexistence/past history of any inflammatory bowel disease; ulcerative colitis or Crohn's disease.
3) Emergency operation.
4) Double cancer.
5) Resection of adjacent organs except gallbladder
6) Use of anticoagulation and/or antiplatelet agents
7) Dysfunction of major organs.
8) During pregnancy and lactation
9) Any other condition that, in the investigator's opinion, places the subject at undue risk by participating in the study.
10
1st name | |
Middle name | |
Last name | Chikashi Shibata |
Tohoku University Hospital
Division of Gastrointestinal Surgery
1-1, Seiryo-machi, Aoba-ku, Sendai, 980-8574, JAPAN
022-717-7205
1st name | |
Middle name | |
Last name | Naoki Tanaka |
Tohoku University Hospital
Division of Gastrointestinal Surgery
1-1, Seiryo-machi, Aoba-ku, Sendai, 980-8574, JAPAN
022-717-7205
n-tanaka@surg1.med.tohoku.ac.jp
Tohoku University Hospital
Division of Gastrointestinal Surgery
non
Other
non
NO
東北大学病院(宮城県)
2011 | Year | 06 | Month | 01 | Day |
Unpublished
Terminated
2011 | Year | 02 | Month | 21 | Day |
2011 | Year | 04 | Month | 01 | Day |
2013 | Year | 03 | Month | 01 | Day |
2013 | Year | 05 | Month | 01 | Day |
2013 | Year | 07 | Month | 01 | Day |
2013 | Year | 09 | Month | 01 | Day |
2011 | Year | 02 | Month | 21 | Day |
2013 | Year | 10 | Month | 22 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000006086